Philadelphia chromosome-like acute lymphoblastic leukemia
Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as - -like ALL, is a high-risk subset with a gene expression profile that shares significant overlap with that of Ph-positive (Ph ) ALL and is suggestive of activated kinase signaling. Although Ph ALL is defined b...
Uložené v:
| Vydané v: | Blood Ročník 130; číslo 19; s. 2064 |
|---|---|
| Hlavní autori: | , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
09.11.2017
|
| Predmet: | |
| ISSN: | 1528-0020, 1528-0020 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as
-
-like ALL, is a high-risk subset with a gene expression profile that shares significant overlap with that of Ph-positive (Ph
) ALL and is suggestive of activated kinase signaling. Although Ph
ALL is defined by
-
fusion, Ph-like ALL cases contain a variety of genomic alterations that activate kinase and cytokine receptor signaling. These alterations can be grouped into major subclasses that include ABL-class fusions involving ABL1, ABL2, CSF1R, and PDGFRB that phenocopy BCR-ABL1 and alterations of CRLF2, JAK2, and EPOR that activate JAK/STAT signaling. Additional genomic alterations in Ph-like ALL activate other kinases, including BLNK, DGKH, FGFR1, IL2RB, LYN, NTRK3, PDGFRA, PTK2B, TYK2, and the RAS signaling pathway. Recent studies have helped to define the genomic landscape of Ph-like ALL and how it varies across the age spectrum, associated clinical features and outcomes, and genetic risk factors. Preclinical studies and anecdotal reports show that targeted inhibitors of relevant signaling pathways are active in specific Ph-like ALL subsets, and precision medicine trials have been initiated for this high-risk ALL subset. |
|---|---|
| AbstractList | Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as BCR-ABL1-like ALL, is a high-risk subset with a gene expression profile that shares significant overlap with that of Ph-positive (Ph+) ALL and is suggestive of activated kinase signaling. Although Ph+ ALL is defined by BCR-ABL1 fusion, Ph-like ALL cases contain a variety of genomic alterations that activate kinase and cytokine receptor signaling. These alterations can be grouped into major subclasses that include ABL-class fusions involving ABL1, ABL2, CSF1R, and PDGFRB that phenocopy BCR-ABL1 and alterations of CRLF2, JAK2, and EPOR that activate JAK/STAT signaling. Additional genomic alterations in Ph-like ALL activate other kinases, including BLNK, DGKH, FGFR1, IL2RB, LYN, NTRK3, PDGFRA, PTK2B, TYK2, and the RAS signaling pathway. Recent studies have helped to define the genomic landscape of Ph-like ALL and how it varies across the age spectrum, associated clinical features and outcomes, and genetic risk factors. Preclinical studies and anecdotal reports show that targeted inhibitors of relevant signaling pathways are active in specific Ph-like ALL subsets, and precision medicine trials have been initiated for this high-risk ALL subset.Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as BCR-ABL1-like ALL, is a high-risk subset with a gene expression profile that shares significant overlap with that of Ph-positive (Ph+) ALL and is suggestive of activated kinase signaling. Although Ph+ ALL is defined by BCR-ABL1 fusion, Ph-like ALL cases contain a variety of genomic alterations that activate kinase and cytokine receptor signaling. These alterations can be grouped into major subclasses that include ABL-class fusions involving ABL1, ABL2, CSF1R, and PDGFRB that phenocopy BCR-ABL1 and alterations of CRLF2, JAK2, and EPOR that activate JAK/STAT signaling. Additional genomic alterations in Ph-like ALL activate other kinases, including BLNK, DGKH, FGFR1, IL2RB, LYN, NTRK3, PDGFRA, PTK2B, TYK2, and the RAS signaling pathway. Recent studies have helped to define the genomic landscape of Ph-like ALL and how it varies across the age spectrum, associated clinical features and outcomes, and genetic risk factors. Preclinical studies and anecdotal reports show that targeted inhibitors of relevant signaling pathways are active in specific Ph-like ALL subsets, and precision medicine trials have been initiated for this high-risk ALL subset. Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as - -like ALL, is a high-risk subset with a gene expression profile that shares significant overlap with that of Ph-positive (Ph ) ALL and is suggestive of activated kinase signaling. Although Ph ALL is defined by - fusion, Ph-like ALL cases contain a variety of genomic alterations that activate kinase and cytokine receptor signaling. These alterations can be grouped into major subclasses that include ABL-class fusions involving ABL1, ABL2, CSF1R, and PDGFRB that phenocopy BCR-ABL1 and alterations of CRLF2, JAK2, and EPOR that activate JAK/STAT signaling. Additional genomic alterations in Ph-like ALL activate other kinases, including BLNK, DGKH, FGFR1, IL2RB, LYN, NTRK3, PDGFRA, PTK2B, TYK2, and the RAS signaling pathway. Recent studies have helped to define the genomic landscape of Ph-like ALL and how it varies across the age spectrum, associated clinical features and outcomes, and genetic risk factors. Preclinical studies and anecdotal reports show that targeted inhibitors of relevant signaling pathways are active in specific Ph-like ALL subsets, and precision medicine trials have been initiated for this high-risk ALL subset. |
| Author | Tasian, Sarah K Hunger, Stephen P Loh, Mignon L |
| Author_xml | – sequence: 1 givenname: Sarah K orcidid: 0000-0003-1327-1662 surname: Tasian fullname: Tasian, Sarah K organization: Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; and – sequence: 2 givenname: Mignon L orcidid: 0000-0003-4099-4700 surname: Loh fullname: Loh, Mignon L organization: Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA – sequence: 3 givenname: Stephen P orcidid: 0000-0002-5492-3957 surname: Hunger fullname: Hunger, Stephen P organization: Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; and |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28972016$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj8tOwzAURC1URB_wBwhlycZwfRMn9hJVFJAqwQLWkV9RTJ06xMmif08RRWI1szhnpFmS2T7uHSHXDO4YE3ivQ4yWIrCKQkmrIkeOZ2TBOAoKgDD71-dkmdInAPuhLsgchayOZrkg8q31QVkX-tarzLRD7GKKnaPB71ymzDS6LBy6vo06qDR6kwU37Vzn1SU5b1RI7uqUK_KxeXxfP9Pt69PL-mFLDUc5Uu0YgtUKRIm64SBVI7liFlTFIReyaXJhTCF4w0RhlTUMbSkrgzrnHDXDFbn93e2H-DW5NNadT8aFoPYuTqlmsiiLHAQvjujNCZ1052zdD75Tw6H-u4vfJoBaQA |
| CitedBy_id | crossref_primary_10_1038_s41408_020_0308_3 crossref_primary_10_3390_ijms222112089 crossref_primary_10_3390_cells11010139 crossref_primary_10_3390_diagnostics15030385 crossref_primary_10_1111_ijlh_13012 crossref_primary_10_1038_s41572_024_00525_x crossref_primary_10_3390_ijms24076805 crossref_primary_10_1016_j_cancergen_2020_03_001 crossref_primary_10_7759_cureus_90563 crossref_primary_10_1007_s10528_024_11018_7 crossref_primary_10_1124_pr_118_016824 crossref_primary_10_1186_s12885_023_10589_9 crossref_primary_10_1016_j_leukres_2022_106925 crossref_primary_10_1002_eji_202250093 crossref_primary_10_1016_j_bneo_2024_100029 crossref_primary_10_1038_s41698_021_00215_x crossref_primary_10_1093_labmed_lmae071 crossref_primary_10_1155_2019_3536517 crossref_primary_10_1080_10428194_2024_2378817 crossref_primary_10_1186_s12935_024_03441_y crossref_primary_10_1182_blood_2021012727 crossref_primary_10_1182_bloodadvances_2020004018 crossref_primary_10_1016_j_leukres_2018_08_009 crossref_primary_10_1111_petr_14024 crossref_primary_10_1002_cnr2_1587 crossref_primary_10_1080_10428194_2021_1933475 crossref_primary_10_1038_s41417_022_00511_z crossref_primary_10_1158_2159_8290_CD_20_1631 crossref_primary_10_1182_bloodadvances_2021005148 crossref_primary_10_3390_ijms25136844 crossref_primary_10_1002_acg2_69 crossref_primary_10_1016_j_clml_2025_09_010 crossref_primary_10_1016_j_ijbiomac_2023_127596 crossref_primary_10_1177_2040620720903531 crossref_primary_10_1111_bjh_16616 crossref_primary_10_1002_pbc_31507 crossref_primary_10_1007_s12288_025_01968_2 crossref_primary_10_1182_blood_2018_02_778530 crossref_primary_10_7124_bc_000A70 crossref_primary_10_1038_s41375_020_0957_z crossref_primary_10_3389_pore_2022_1610570 crossref_primary_10_1016_j_beha_2019_101095 crossref_primary_10_1016_j_ijbiomac_2021_08_194 crossref_primary_10_1038_s41375_021_01326_x crossref_primary_10_1016_j_beha_2019_101096 crossref_primary_10_1038_s41375_019_0378_z crossref_primary_10_1016_j_bcmd_2018_09_002 crossref_primary_10_1097_MPH_0000000000001267 crossref_primary_10_1016_j_ejca_2021_12_029 crossref_primary_10_1016_S0140_6736_19_33018_1 crossref_primary_10_1002_ajh_25256 crossref_primary_10_1038_s41698_023_00479_5 crossref_primary_10_1182_blood_2024024455 crossref_primary_10_1002_cncr_31669 crossref_primary_10_1182_bloodadvances_2019000163 crossref_primary_10_1016_j_ejcped_2025_100304 crossref_primary_10_1007_s00428_022_03402_8 crossref_primary_10_1016_j_exphem_2018_07_007 crossref_primary_10_1186_s13287_021_02659_1 crossref_primary_10_3389_fcell_2022_942053 crossref_primary_10_1080_10428194_2025_2521658 crossref_primary_10_3390_genes14030691 crossref_primary_10_1016_j_medj_2024_11_003 crossref_primary_10_1080_07853890_2018_1564359 crossref_primary_10_1182_blood_2018_03_833665 crossref_primary_10_3390_diagnostics13091589 crossref_primary_10_1002_ctm2_1309 crossref_primary_10_1002_mco2_70360 crossref_primary_10_3390_cancers12123498 crossref_primary_10_1016_j_beha_2020_101193 crossref_primary_10_1016_j_clml_2021_12_006 crossref_primary_10_1111_ijlh_14415 crossref_primary_10_1182_bloodadvances_2021005634 crossref_primary_10_1007_s11899_018_0456_8 crossref_primary_10_1038_s41598_025_95356_5 crossref_primary_10_5858_arpa_2024_0082_OA crossref_primary_10_1016_j_modpat_2025_100741 crossref_primary_10_1186_s13287_024_03869_z crossref_primary_10_32725_jab_2024_024 crossref_primary_10_1007_s40291_025_00775_9 crossref_primary_10_3892_ol_2024_14323 crossref_primary_10_3389_fcell_2025_1650810 crossref_primary_10_3389_fgene_2020_00076 crossref_primary_10_5858_arpa_2019_0194_RA crossref_primary_10_1002_hem3_117 crossref_primary_10_1002_pbc_27644 crossref_primary_10_1002_hon_2701 crossref_primary_10_1016_j_humpath_2023_03_002 crossref_primary_10_7759_cureus_10696 crossref_primary_10_3390_biomedicines12010089 crossref_primary_10_3389_fonc_2021_802832 crossref_primary_10_1182_bloodadvances_2022008032 crossref_primary_10_3390_cancers13164068 crossref_primary_10_1002_ajh_26966 crossref_primary_10_1111_ijlh_13698 crossref_primary_10_1182_blood_2018_04_841676 crossref_primary_10_1080_10428194_2020_1861275 crossref_primary_10_1016_j_ejcped_2024_100200 crossref_primary_10_3389_fonc_2023_1162694 crossref_primary_10_3390_brainsci12101349 crossref_primary_10_1097_FPC_0000000000000554 crossref_primary_10_1016_j_jmoldx_2024_07_004 crossref_primary_10_1080_14656566_2021_1931683 crossref_primary_10_1182_blood_2020006846 crossref_primary_10_3390_cancers13225658 crossref_primary_10_1016_S1470_2045_19_30031_2 crossref_primary_10_1038_s41588_022_01159_z crossref_primary_10_1159_000490121 crossref_primary_10_1038_s41375_021_01277_3 crossref_primary_10_1111_bjh_17879 crossref_primary_10_3390_cancers13164171 crossref_primary_10_1111_imr_13180 crossref_primary_10_1007_s00277_023_05456_3 crossref_primary_10_2174_0109298673267738231129104216 crossref_primary_10_1016_j_ncrna_2025_09_005 crossref_primary_10_3390_diagnostics13081486 crossref_primary_10_1016_j_ejphar_2019_172641 crossref_primary_10_1186_s12887_024_04991_w crossref_primary_10_3389_fonc_2022_1072806 crossref_primary_10_1016_j_prp_2024_155161 crossref_primary_10_1080_15384101_2024_2306756 crossref_primary_10_1001_jamanetworkopen_2019_2906 crossref_primary_10_1016_j_clml_2019_08_003 crossref_primary_10_1038_s41416_023_02294_y crossref_primary_10_1182_blood_2022015850 crossref_primary_10_1055_s_0043_1766133 crossref_primary_10_1016_j_beha_2018_09_003 crossref_primary_10_3390_cancers17172746 crossref_primary_10_1002_cncr_33933 crossref_primary_10_1182_blood_2024026482 crossref_primary_10_1038_s43018_022_00370_5 crossref_primary_10_1186_s13045_020_00905_2 crossref_primary_10_1002_cnr2_1706 crossref_primary_10_3390_cancers16050858 crossref_primary_10_1007_s12561_024_09437_6 crossref_primary_10_1007_s11899_020_00597_y crossref_primary_10_1038_s41375_024_02421_5 crossref_primary_10_1158_1078_0432_CCR_21_0553 crossref_primary_10_1542_pir_2018_0192 crossref_primary_10_1016_j_yao_2021_02_014 crossref_primary_10_1182_blood_2023023153 crossref_primary_10_1053_j_semdp_2023_04_003 crossref_primary_10_3389_fonc_2023_1276695 crossref_primary_10_3390_metabo10080332 crossref_primary_10_1002_ardp_202400890 crossref_primary_10_1136_bcr_2018_226497 crossref_primary_10_1007_s00277_020_04221_0 crossref_primary_10_1182_bloodadvances_2017014704 crossref_primary_10_3390_cancers16020337 crossref_primary_10_1038_s41598_021_91760_9 crossref_primary_10_3389_fvets_2020_536390 crossref_primary_10_1016_j_semcancer_2020_10_013 crossref_primary_10_1053_j_seminhematol_2020_08_001 crossref_primary_10_3390_jcm10091926 crossref_primary_10_1111_ajco_14041 crossref_primary_10_1038_s41388_020_01567_7 crossref_primary_10_1016_j_beha_2021_101331 crossref_primary_10_3389_fonc_2023_1291570 crossref_primary_10_1038_s41375_018_0144_7 crossref_primary_10_1007_s12288_018_0997_y crossref_primary_10_1172_JCI134424 crossref_primary_10_1186_s13062_019_0255_8 crossref_primary_10_1038_s41375_021_01248_8 crossref_primary_10_1016_j_mayocp_2019_04_030 |
| ContentType | Journal Article |
| Copyright | 2017 by The American Society of Hematology. |
| Copyright_xml | – notice: 2017 by The American Society of Hematology. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1182/blood-2017-06-743252 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology Anatomy & Physiology |
| EISSN | 1528-0020 |
| ExternalDocumentID | 28972016 |
| Genre | Journal Article Review Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIGMS NIH HHS grantid: P50 GM115279 – fundername: NCI NIH HHS grantid: K08 CA184418 |
| GroupedDBID | --- -~X .55 0R~ 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6J9 AAEDW AALRI AAXUO ABOCM ACGFO ADBBV ADVLN AENEX AFETI AFOSN AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD EX3 F5P FDB FRP GS5 GX1 H13 IH2 K-O KQ8 L7B LSO MJL N9A NPM OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV 7X8 ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP EFKBS |
| ID | FETCH-LOGICAL-c529t-be120dba0862bf509af95a1d0a750389ff38cc485f184dadc12d697c2b3552b12 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 200 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000415297200008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1528-0020 |
| IngestDate | Sun Nov 09 11:36:37 EST 2025 Wed Feb 19 02:30:38 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 19 |
| Language | English |
| License | 2017 by The American Society of Hematology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c529t-be120dba0862bf509af95a1d0a750389ff38cc485f184dadc12d697c2b3552b12 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-5492-3957 0000-0003-4099-4700 0000-0003-1327-1662 |
| OpenAccessLink | https://dx.doi.org/10.1182/blood-2017-06-743252 |
| PMID | 28972016 |
| PQID | 1946430854 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1946430854 pubmed_primary_28972016 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-11-09 20171109 |
| PublicationDateYYYYMMDD | 2017-11-09 |
| PublicationDate_xml | – month: 11 year: 2017 text: 2017-11-09 day: 09 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Blood |
| PublicationTitleAlternate | Blood |
| PublicationYear | 2017 |
| SSID | ssj0014325 |
| Score | 2.6325321 |
| SecondaryResourceType | review_article |
| Snippet | Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as
-
-like ALL, is a high-risk subset with a gene expression profile... Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as BCR-ABL1-like ALL, is a high-risk subset with a gene expression... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2064 |
| SubjectTerms | Animals Fusion Proteins, bcr-abl - genetics Fusion Proteins, bcr-abl - metabolism Humans Philadelphia Chromosome Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism Signal Transduction - genetics Translocation, Genetic |
| Title | Philadelphia chromosome-like acute lymphoblastic leukemia |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28972016 https://www.proquest.com/docview/1946430854 |
| Volume | 130 |
| WOSCitedRecordID | wos000415297200008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEB5868VH6_vBCuIt2KbZTXISFcVLSw8KvZU8sbTuVtsK_fdOsls8CYKXZQ_7zMxmvm9mNh_AVciscZE1iLVCEsZanGidZcRYrxSTygjLotgE73RErye7VcJtUrVVLubEOFHbwoQc-Q2SbQyeCBDY7fiDBNWoUF2tJDSWYbWFUCZ4Ne_9VBFYK4quYogSJOCi6tc5hNQ3ZVs4DXM0UmoejqS_g8wYbJ52_vuYu7BdwczkrvSLPVhyeQ3qdzlS7Pd5cp3Exs-YUa_B-v1ib_NhIf9Wg412VXWvgwxZl7Cc5PhtoBLzFjr4JsW7I6PB0CXKzKYuGc3RLQqNWBzvmIzcbIhXUvvw-vT48vBMKskFYlIqp0S7Jm1YrQLR0R7BhPIyVU3bUDwuxed9SxjDROqRGVplTZPaTHJDNeIWqpv0AFbyIndHkCifWhE0C4XnTGsmnfbIxTFqIkkSjh7D5WIE-_hqoU6hclfMJv2fMTyGw9IM_XG59kYf-SFHq2Unfzj7FLaigUMSWJ7BqscP2p3DmvmaDiafF9FXcNvptr8BfrLHyw |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Philadelphia+chromosome-like+acute+lymphoblastic+leukemia&rft.jtitle=Blood&rft.au=Tasian%2C+Sarah+K&rft.au=Loh%2C+Mignon+L&rft.au=Hunger%2C+Stephen+P&rft.date=2017-11-09&rft.issn=1528-0020&rft.eissn=1528-0020&rft.volume=130&rft.issue=19&rft.spage=2064&rft_id=info:doi/10.1182%2Fblood-2017-06-743252&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-0020&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-0020&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-0020&client=summon |